A new generation of

Immunotherapy

A recipient of FDA's Fast Track designation, Diakonos is a clinical-stage biotechnology company developing a groundbreaking Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers.

Learn More

Redefining the Potential of Immunotherapy

Dentritic
Cell Vaccines

Developed at the Texas Medical Center, DOC1021 represents a novel approach to fighting cancer that harnesses the body’s natural anti-viral immune response.

At the core of DOC1021 is Diakonos’ proprietary “double-loading” technique. This patented process tricks the body into perceiving cancer cells as virally infected cells, mirroring the natural detection and elimination process for viral infections.

Learn More

Powered by a

Groundbreaking
Discovery on the
Immune System

DOC1021 is based on a discovery on how dendritic cells are able to detect and respond to viral threats. Based on Diakonos’ research, it is now known that dendritic cells compare antigens presented on MHC Class 1 and 2.

When identical antigens are detected on both MHC Class 1 and 2, dendritic cells mobilize formidable CD8 CD161 T cells to destroy what the immune system believes are infected cells throughout the body.

Learn More About Our Research

Diakonos Oncology

News & Media

Diakonos Oncology to Present at Biotech Showcase 2025

SNO 2024 Presentation: DOC1021 Cell-Based Vaccination as Adjuvant Therapy for Glioblastoma: Phase I Clinical Trial Analysis

Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer

Company also names Deancy Okoebor Director of Clinical Operations and Eva Highberg Schumann Project Coordinator as it prepares for a Phase 2 trial of its unique dendritic cell vaccine for glioblastoma HOUSTON–(November 18, 2024)–Diakonos Oncology Corp., a clinical stage immuno-oncology company, announced today that Laura Aguilar, M.D., Ph.D., has been appointed Chief Medical Officer. Dr. Aguilar, a […]

Clinical Trials

Underway

Discover our treatment centers and find out which one is best for you.

Multi-site<br /> Phase 2, <a href="https://clinicaltrials.gov/study/NCT06805305?term=diakonos&rank=1">NCT06805305</a>

Glioblastoma

Multi-site
Phase 2, NCT06805305

This is a randomized, prospective, multi-center, open-label study to evaluate the safety and efficacy of the DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care (SOC) on the overall survival of adult patients with newly diagnosed Glioblastoma (GBM) compared to SOC alone.

Baylor College of MedicinePhase 1, <a href="https://clinicaltrials.gov/study/NCT04157127?term=NCT04157127&limit=10&rank=1">NCT04157127</a>

Pancreatic Adenocarcinoma

Baylor College of MedicinePhase 1, NCT04157127

Conducted in partnership with the Baylor College of Medicine, this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous Dendritic Cells (DCs) to Pancreatic Cancer patients as adjuvant therapy following completion of standard chemotherapy.

Serving the Patient,
not the Cancer.

Expanded Access Program